Financial Performance - The company's revenue for Q1 2025 reached ¥3,098,813,569.89, representing a 16.03% increase compared to ¥2,670,740,738.16 in the same period last year[6] - Net profit attributable to shareholders was ¥305,575,186.04, up 32.54% from ¥230,557,834.70 year-on-year[6] - The adjusted net profit attributable to shareholders was ¥349,441,031.17, reflecting a 3.14% increase from ¥338,816,299.13 in the previous year[6] - Total revenue for the period reached CNY 3,098,813,569.89, an increase of 15.9% compared to CNY 2,670,740,738.16 in the previous period[35] - Net profit for the period was CNY 279,654,565.09, representing a 29.5% increase from CNY 215,919,833.12 in the prior period[36] - The company reported a profit before tax of RMB 363,587,000, compared to RMB 268,619,000 in the previous year, an increase of 35.4%[42] - Total comprehensive income for the period reached RMB 389,670,737.53, compared to RMB 162,642,198.05 in the previous period, representing an increase of approximately 139.5%[37] Revenue Breakdown - Revenue from laboratory services was ¥1,857,202,616.77, a 15.74% increase from ¥1,604,576,678.01 year-on-year, with a gross margin of 45.54%[8] - Revenue from CMC (small molecule CDMO) services was ¥693,023,486.59, up 19.05% from ¥582,104,488.92, with a gross margin of 30.44%[8] - Revenue from clinical research services reached ¥447,320,929.08, a 14.25% increase from ¥391,531,326.06, with a gross margin of 11.76%[8] - Revenue from the top 20 global pharmaceutical companies was ¥455,746,000, a 29.05% increase, accounting for 14.71% of total revenue[9] Shareholder Metrics - Basic earnings per share increased by 33.54% to CNY 0.1736, reflecting the growth in net profit attributable to shareholders[14] - Diluted earnings per share rose by 33.51% to CNY 0.1733, also attributed to the increase in net profit[15] - The total number of common shareholders at the end of the reporting period was 79,841[20] - The company announced a profit distribution plan for the year 2024, which is expected to enhance shareholder value[28] Cash Flow and Assets - The company's cash flow from operating activities amounted to ¥852,829,144.27, a 14.38% increase compared to ¥745,630,586.78 in the same period last year[6] - Cash flow from investing activities resulted in a net outflow of RMB 1,212,095,238.52, worsening from a net outflow of RMB 467,094,044.67 in the previous period[40] - Cash flow from financing activities showed a net outflow of RMB 98,926,715.92, an improvement compared to a net outflow of RMB 1,512,600,594.24 last period[41] - The total current assets decreased from CNY 7,608,179,522.72 to CNY 7,384,443,685.17, representing a decline of approximately 2.95%[30] - Cash and cash equivalents decreased from CNY 1,689,916,082.15 to CNY 1,262,763,166.96, a reduction of about 25.3%[30] Expenses and Liabilities - Total operating costs amounted to CNY 2,713,717,115.43, up from CNY 2,439,362,705.75, reflecting a growth of 11.2%[35] - Research and development expenses grew by 30.56% to CNY 122,210,590.15, indicating a continued commitment to R&D investment[18] - Income tax expenses rose by 59.27% to CNY 83,932,205.84, corresponding to the increase in total profit[19] - The total liabilities decreased slightly to CNY 9,686,700,206.35 from CNY 9,704,526,037.38, a reduction of 0.2%[33] Other Financial Metrics - Other comprehensive income increased significantly by 1,370.30% to CNY 98,545,941.98, driven by foreign currency translation differences and cash flow hedging[18] - The company's total non-current assets increased to CNY 16,948,379,035.81 from CNY 16,319,218,798.51, marking a growth of 3.9%[31] - The equity attributable to the parent company increased to RMB 14,042,172 thousand from RMB 13,619,335 thousand, marking a growth of 3.1%[44] - The company's goodwill increased to RMB 2,947,429 thousand from RMB 2,760,736 thousand, reflecting a growth of 6.8%[43]

本期导读： 医疗保健公司逆势布局，出资活跃度创今年以来新高，主要围绕生物医药产业布局。从地域上来 看，浙江省上市公司势头最猛烈，无论是出资频次还是规模，都位居前列。 作者丨FOFWEEKLY 本期推荐阅读5分钟 19 20 30.00 15 20.00 10 10.00 5 0 0.00 3月 2月 3月 4月 2月 ୧ 넘 7月 8月 o be 10月 11月 12月 1月 2024年 2025年 出资规模(亿元) = 一 出资次数 3月份，上交所、深交所共有19家上市公司（含子公司）对私募股权基金进行了出资 共投向19支基金,出资笔数共计19笔,已披露金额的出资额合计7.54亿元,平均单笔出 资额0.4亿元。 近一年出资基金的平均规模 25.00 20.00 19.47 15.00 14.68 10.00 10.19 9 94 5.00 6.31 6.23 5.69 5.37 4.78 4.35 3.84 2.98 0.00 4月 2月 ୧用 7月 8月 9月 10月 11月 12月 1月 2月 3月 2024年 2025年 3月参与出资基金的平均规模整体较低,上市公司出资规模与活跃度连续三个月下降。 医 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-026 康龙化成（北京）新药技术股份有限公司 关于非执行董事辞职暨 补选公司第三届董事会非执行董事的公告 事会任期届满之日止。 胡柏风先生在任职期间勤勉尽责，致力于公司的规范运作和健康发展，并凭 借自身积累的丰富投资经验，为公司可持续发展提供了诸多宝贵建议，公司董事 会对胡柏风先生在任职期间为公司及董事会所做出的贡献表示衷心感谢！ 特此公告。 康龙化成（北京）新药技术股份有限公司董事会 2025 年 4 月 28 日 2 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第三届董事会第十四次会议，审议通过了《关于补选公司第三届董 事会非执行董事的议案》。胡柏风先生因本职工作调整，申请辞去公司第三届董 事会非执行董事及董事会战略委员会委员职务（第三届董事会原定任期至 2026 年 6 月 20 日），辞职后胡柏风先生将不再担任公司任何职务。胡柏风先生自愿继 续履行非执行董事及董事会战略委员会委员职责至公司股东 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-024 康龙化成（北京）新药技术股份有限公司 第三届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）第三届董事 会第十四次会议于 2025 年 4 月 25 日上午 11：00 以通讯方式召开，本次会议通 知及会议材料于 2025 年 4 月 11 日以邮件形式向全体董事发出。会议应出席董事 8 名，实际出席董事 8 名。本次会议由公司董事长 Boliang Lou 博士主持，公司 部分高级管理人员列席了本次会议。本次会议的召集和召开符合《中华人民共和 国公司法》等有关法律、行政法规、部门规章、规范性文件和《康龙化成（北京） 新药技术股份有限公司章程》的规定。 二、董事会会议审议情况 与会董事审议并以记名投票方式通过了以下议案： （一）审议通过《关于 2025 年第一季度报告的议案》 董事会认为：公司编制的《2025 年第一季度报告》符合法律、行政法规、中 国证监会和深圳证券交易所的规定，报 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥3,098,813,569.89, representing a 16.03% increase compared to ¥2,670,740,738.16 in the same period last year[4] - Net profit attributable to shareholders was ¥305,575,186.04, up 32.54% from ¥230,557,834.70 year-on-year[4] - The adjusted net profit under non-IFRS was ¥349,441,031.17, a 3.14% increase from ¥338,816,299.13 in the previous year[4] - The company's cash flow from operating activities was ¥852,829,144.27, reflecting a 14.38% increase compared to ¥745,630,586.78 in the same period last year[4] - Total operating revenue for the current period reached ¥3,098,813,569.89, an increase of 15.9% compared to ¥2,670,740,738.16 in the previous period[24] - Net profit for the current period was ¥279,654,565.09, compared to ¥215,919,833.12 in the previous period, representing an increase of 29.5%[25] - Basic earnings per share increased by 33.54% year-on-year to RMB 0.1736, reflecting the growth in net profit[12] - Basic earnings per share increased to 0.1736 from 0.1300, marking a growth of 33.1%[26] Revenue Breakdown - Revenue from laboratory services was ¥1,857,202,616.77, with a gross margin of 45.54%, up from 44.14% year-on-year[5] - Revenue from CMC (small molecule CDMO) services increased by 30.44% to ¥693,023,486.59, with a gross margin of 30.44%[5] - Revenue from clinical research services was ¥447,320,929.08, showing an 11.76% increase year-on-year[5] - Revenue from North American clients was ¥200,338.79 million, a 16.81% increase, accounting for 64.65% of total revenue[7] - The company signed new orders with a year-on-year growth of over 10%, particularly in laboratory services and CMC services[7] Assets and Liabilities - Total assets at the end of the reporting period were ¥24,332,822,720.98, a 1.69% increase from ¥23,927,398,321.23 at the end of the previous year[4] - Total current assets decreased to CNY 7,384,443,685.17 from CNY 7,608,179,522.72, representing a decrease of approximately 2.95%[21] - Long-term equity investments increased to CNY 727,361,422.75 from CNY 648,983,149.15, an increase of about 12.06%[21] - Total liabilities increased to CNY 7,206,443,000.00, reflecting a growth of approximately 3.5% compared to the previous period[21] - The total liabilities decreased slightly to ¥9,686,700,206.35 from ¥9,704,526,037.38, a reduction of 0.2%[23] Expenses and Taxation - Research and development expenses increased by 30.56% year-on-year to RMB 122,210,590.15, indicating a continued commitment to R&D investment[12] - Total income tax expenses rose by 59.27% year-on-year to RMB 83,932,205.84, corresponding to the increase in total profit[13] - The company paid $1,398,959,106.45 to employees, an increase from $1,313,660,048.35[29] - The company reported a total tax payment of $146,967,843.36, a decrease from $155,141,776.68[29] Comprehensive Income - Other comprehensive income surged by 1,370.30% year-on-year to RMB 98,545,941.98, mainly due to increases in foreign currency translation differences and cash flow hedging[12] - Other comprehensive income after tax for the current period was ¥110,016,172.44, compared to a loss of ¥53,277,635.07 in the previous period[26] - The company reported a total comprehensive income of ¥389,670,737.53, up from ¥162,642,198.05, indicating a significant increase of 139.5%[26] Cash Flow - Cash inflow from operating activities totaled ¥3,472,049,631.92, compared to ¥3,137,994,335.42 in the previous period, indicating a rise of 10.7%[28] - The net cash flow from operating activities was $852,829,144.27, an increase of 14.4% compared to $745,630,586.78 in the previous period[29] - The total cash outflow from investing activities was $2,181,721,151.04, up from $1,578,554,143.99, resulting in a net cash flow from investing activities of -$1,212,095,238.52[29] - Cash inflow from financing activities was $148,201,518.67, compared to $104,094,412.63 in the previous period, while cash outflow was $247,128,234.59, down from $1,616,695,006.87[29] - The ending balance of cash and cash equivalents was $1,173,579,263.69, down from $4,561,507,266.77[29] Future Plans and Investments - The company plans to invest in new product development and market expansion strategies in the upcoming fiscal year[18] - The company is collaborating with professional institutions for equity investments, indicating a strategic move towards enhancing its investment portfolio[18] - The company has announced a profit distribution plan for the fiscal year 2024, which is expected to be disclosed in detail soon[18] Miscellaneous - The company did not execute any new accounting standards adjustments for the first quarter report[30] - The first quarter report was not audited[30]

Investment Rating - The industry view for mid-cap CRO/CDMOs is rated as Attractive [5] Core Insights - Direct tariff exposure for major China CRO/CDMO companies is estimated to be between 0%-10%, which is manageable for most leading firms in the sector [3][8] - Increasing macro uncertainties, including tariffs and funding dynamics, are expected to lead to softer funding beta and more cautious R&D budgets in 2025 [3][21] - The FDA's proposal to phase out animal testing is unlikely to have an immediate impact on most CROs, as alternatives are limited [8][14] Company-Level Picks - Pharmaron-H is highlighted as the most preferred pick due to its strong alpha from CMC and minimal tariff exposure [4] - GenScript is favored for its turnaround in non-cell business and robust contributions from its CGT investment [4] - Asymchem is noted for its growth in the GLP-1 area, though there are concerns about its overseas facility loss in 2025 [4] - Joinn Lab and Tigermed are viewed positively for their long-term prospects, despite expectations of a slower domestic funding recovery [4] Market Dynamics - The report indicates that the general outlook for CRO/CDMO companies is improving in 2025, but remains softer than earlier expectations due to disrupted global funding momentum [21] - Quality players with unique barriers and visionary overseas facility deployment are expected to outperform their peers [21] Financial Forecasts and Valuations - Tigermed's revenue growth forecasts for 2025-2027 have been adjusted to 3.1%, 8.1%, and 11.6% YoY, reflecting a cautious outlook [26] - The price target for Tigermed has been reduced from Rmb57.5 to Rmb37.7 due to updated earnings estimations [28]

Group 1 - The core point of the article highlights the performance of the China Europe Medical Innovation Stock C fund, which has a latest net value of 1.1626 yuan, reflecting a decrease of 1.43% [1] - The fund's performance over the past month shows a return of 3.72%, ranking 37 out of 541 in its category; over the past three months, it has achieved a return of 20.12%, ranking 10 out of 539; and since the beginning of the year, it has returned 17.16%, ranking 13 out of 537 [1] - The top ten holdings of the fund account for a total of 75.62%, with significant positions in companies such as WuXi AppTec (10.35%), Kelun-Biotech (10.15%), and WuXi Biologics (9.82%) [1] Group 2 - The China Europe Medical Innovation Stock C fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at Guotai Junan Securities and Minsheng Zhiyin Fund Management [2]

证券代码：300759 证券简称：康龙化成 康龙化成（北京）新药技术股份有限公司投资者关系活动记录表 编号：2025-03 问：请问目前中美关税情况对公司是否有影响？ 答：截至目前，美国加征关税对公司业务产生的影响有限。公司主要 是为客户提供研发服务，CMC 涉及的商业化货物出口的业务占比较 小，目前公司并未收到客户或其他合作伙伴向公司反馈关税问题对业 务合作造成影响。对于宏观的不确定性风险，公司会密切关注相关政 策动向。地缘政治背景下，也敬请投资者注意投资风险。 问：小分子 CDMO 产能利用率和毛利率趋势？ 答：从目前公司管线看，预计公司交付项目和收入规模会进一步提 高，产能利用率和毛利率也会同比提升。 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系 活动类别 | □新闻发布会 √路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称及 | | | 人员姓名 | Manulife、TruMed、SinoPac、Library Group、华凯资产管理 | | 时 间 | 年 月 日 2025 4 24 | | ...

Group 1 - The core viewpoint of the news is that the implementation plan for the digital transformation of the pharmaceutical industry in China aims to achieve comprehensive digitalization by 2030, enhancing innovation capabilities and establishing a complete industrial ecosystem [1][2] - The plan includes four major actions: empowering digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation, with 14 key tasks to improve the overall capability of the pharmaceutical industry's digital transformation [1][2] - The focus areas of the plan include pharmaceutical research and development, production, management decision-making, quality assurance, circulation and traceability, and contract research and production services, providing a clear pathway for collaboration between pharmaceutical companies and IT service providers [1][2] Group 2 - The release of the plan signifies a new phase of high-quality development driven by data and intelligent empowerment in the pharmaceutical industry, which is expected to reshape the industry landscape through technologies like AI in drug development and smart manufacturing [2] - The AI pharmaceutical market is projected to grow significantly, from $1.38 billion in 2023 to $2.994 billion by 2026, with a compound annual growth rate of 30.47% from 2021 to 2026 [3] - Major pharmaceutical companies are expected to enhance drug discovery efficiency by over 50% through AI integration, which will lead to better resource allocation in research and healthcare [3] Group 3 - Notable companies in the sector include WuXi AppTec, which is projected to achieve a revenue of 39.241 billion yuan in 2024, with a 5.2% year-on-year growth excluding COVID-19 projects [4] - Kanglong Chemical is expected to report a revenue of 12.276 billion yuan in 2024, reflecting a 6.39% year-on-year increase, while its net profit is anticipated to grow by 12.01% [4] - Yidu Technology focuses on AI in healthcare, providing innovative solutions across various fields, including public health and new drug development [4]

Core Insights - The Chinese innovative drug market is projected to exceed 1.13 trillion yuan in 2024, with expectations to approach 2.3 trillion yuan by 2030, indicating a high growth trend in the sector [1] - The Hong Kong pharmaceutical ETF (159718) has shown a recent decline of 0.28%, but has increased by 7.16% over the past week [1] - The liquidity of the Hong Kong pharmaceutical ETF is active, with a turnover of 17.21% and a transaction volume of 50.91 million yuan [2] Group 1: Market Performance - As of April 24, 2025, notable stock performances include Xintai Medical (02291) up 13.86%, Ascentage Pharma-B (06855) up 7.36%, and Innovent Biologics (01801) up 4.18% [1] - The Medical Innovation ETF (516820) has a recent turnover of 1.7% and a transaction volume of 28.42 million yuan, with an average daily transaction of 53.10 million yuan over the past month [4] Group 2: Index and Weighting - The CSI Hong Kong Stock Connect Healthcare Index (930965) includes 50 liquid and large-cap healthcare companies, with the top ten stocks accounting for 59.76% of the index [6] - The top ten stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) account for 66.49%, indicating a concentration in leading companies [9] Group 3: Investment Outlook - The manager of Ping An Healthcare Fund, Zhou Sicong, emphasizes that the export of innovative drugs is largely unaffected by U.S. tariff policies due to factors such as high profit margins and the nature of intellectual property [2] - The innovative drug sector is expected to have a promising outlook for Chinese companies, with investors advised not to overreact to short-term policy fluctuations [2]